Different clinical trials indicated a beneficial effect of GLP-1 analogs on obesity; thus, liraglutide was also licensed as a weight loss agent, with encouraging results in phase III clinical trials [34,52]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.